Brief Article
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2014; 20(12): 3335-3342
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3335
Table 1 Clinicopathological characteristics of hepatocellular carcinoma patients who underwent initial hepatectomy in the full analysis set and one-to-one propensity score-matched pairs
VariablesFull analysis set
Propensity score-matched pairs
A (n = 110)NA (n = 158)P valueA (n = 44)NA (n = 44)P value
Gender (M:F)97:13133:250.45538:638:6NA
Age (yr)68 (64-70)66 (64-68)0.86264.9 ± 10.264.5 ± 9.50.838
Etiology
(B:C:BC:NBNC)50:32:1:2770:61:6:210.03519:18:1:624:12:1:70.602
Background (N:CH:L)16:56:389:49:100< 0.0014:20:205:14:250.422
Histology (W:M:P)50:32:1:2729:94:350.1386:30:88:28:80.836
Albumin (mg/dL)3.91 ± 0.423.86 ± 0.470.3213.99 ± 0.343.92 ± 0.410.379
Bilirubin (mg/dL)0.6 (0.6-0.6)0.8 (0.7-0.9)< 0.0010.68 ± 0.260.72 ± 0.390.545
PT (%)93.3 ± 12.290.6 ± 13.60.10692.4 ± 11.592.5 ± 12.40.948
ICGR15 (%)8.5 (7.4-9.9)13 (10.8-15)< 0.00110.4 ± 5.613.5 ± 8.80.053
Child-Pugh score (A:B)109:1153:50.41944:044:0NA
MELD score7.68 ± 2.737.58 ± 1.390.6747.78 ± 3.217.37 ± 1.290.448
Tumor size (cm)4.2 (3.5-5.5)2.5 (2.2-3.0)< 0.0013 (2.5-3.5)3 (2.3-3.5)0.904
No. of tumors1 (1-1)1 (1-1)0.7611 (1-1)1 (1-1)0.554
VI (-:+:++)75:18:17124:25:90.02734:7:331:10:30.716
OT (min)400 (364-439)280 (260-300)< 0.001340.1 ± 105.8322.7 ± 96.80.441
Blood loss (mL)435 (380-600)300 (230-390)< 0.001400 (310-482)355 (270-560)0.926
Blood transfusion (U)1.3 ± 3.60.5 ± 2.30.0490.4 ± 1.40.5 ± 1.60.833
BMI23.19 ± 3.2723.61 ± 3.380.31323.57 ± 3.0122.83 ± 3.130.263
Platelets15.6 (13.3-17.1)12.6 (11.7-14.2)0.50413.45 ± 4.7116.41 ± 13.690.178
AST (IU/L)36 (31-41)36 (31-45)0.20640 (33-46)33 (30-48)0.439
ALT (IU/L)34 (29-38)32 (28-37)0.41338 (32-43)29 (27-39)0.103
MELD7.03 (6.87-7.19)7.12 (6.87-7.42)0.6747.10 (6.87-7.39)7.03 (6.43-7.29)0.396
BTR6.07 (5.60-6.59)5.42 (5.07-5.84)< 0.0015.89 (4.99-6.50)5.73 (5.06-6.02)0.277
Hyaluronate (ng/mL)98 (76-132)155 (128-196)< 0.001103 (66-139)137 (104-187)0.204
HGF (ng/mL)0.32 (0.29-0.36)0.36 (0.32-0.39)0.0690.33 ± 0.140.39 ± 0.150.066
AFP (ng/mL)21.2 (11.2-80.9)13.7 (8-29.5)0.17811.7 (6.5-38.4)14.5 (5.8-46.4)0.902
PIVKA (mAU/mL)228 (90-639)35 (27-53)0.01538 (24-158)30 (23-66)0.721
Table 2 Univariate and multivariate analysis of prognostic factors in the one-to-one propensity score-matched pairs
Overall survivalUnivariate analysis
Multivariate analysis
Prognostic factorsHR95%CIP valueHR95%CIP value
Anatomical resection0.4560.211-0.9830.0390.5460.205-1.4530.226
Female gender0.6730.157-2.8770.572
Age0.9940.955-1.0330.747
Background (N + CH)0.8670.412-1.8250.707
Histology (W + M)0.4420.194-1.0050.068
Albumin0.5360.187-1.5340.249
Bilirubin1.2470.375-4.1450.721
Prothrombin time0.9840.951-1.0190.371
ICGR151.1011.047-1.158< 0.0011.0590.990-1.1340.097
Tumor size1.1511.069-1.2410.0011.1650.977-1.3890.089
No. of tumors1.0750.728-1.5880.723
Absence of VI0.2320.109-0.496< 0.0010.2280.092-0.5680.002
Operative Time1.0030.999-1.0060.189
Blood loss1.0021.001-1.0020.0011.0011.000-1.0020.179
Blood transfusion1.1170.914-1.3640.316
Body mass index0.9570.839-1.0910.509
Platelets1.0231.000-1.0470.109
AST1.0241.012-1.0370.0011.0100.994-1.0260.209
ALT1.0050.992-1.0190.472
MELD1.0670.966-1.1790.278
BTR0.7720.557-1.0680.084
Hyaluronate1.0010.999-1.0030.234
HGF43.1792.321-803.290.01552.3661.310-2094.10.035
Alpha-fetoprotein11.000-1.0000.138
PIVKA11.000-1.0000.534